Insulin glulisine, insulin lispro and regular human insulin show comparable end-organ metabolic effects in type 1 diabetes underlining physiologic insulin signaling

被引：0
|
作者：
Horvath, K
Bock, G
Regittnig, W
Bodenlenz, M
Wutte, A
Theobald, K
Schweitzer, MA
Fuerstrecktenwald, S
Pieber, TR
机构：
来源：
DIABETES | 2005年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A332 / A332
页数：1
相关论文
共 50 条
  • [1] Insulin glulisine, insulin lispro and regular human insulin show comparable end-organ metabolic effects: an exploratory study
    Horvath, K.
    Bock, G.
    Regittnig, W.
    Bodenlenz, M.
    Wutte, A.
    Plank, J.
    Magnes, C.
    Sinner, F.
    Rst-Recktenwald, S. Fu
    Theobald, K.
    Pieber, T. R.
    [J]. DIABETES OBESITY & METABOLISM, 2008, 10 (06): : 484 - 491
  • [2] Pharmacodynamics and pharmacokinetics of insulin glulisine compared with insulin lispro and regular human insulin in patients with Type 2 diabetes
    Kapitza, C
    Becker, RHA
    Frick, AD
    Heise, T
    Rave, K
    [J]. DIABETOLOGIA, 2004, 47 : A265 - A265
  • [3] Efficacy and safety of insulin glulisine and insulin lispro combined with insulin glargine in patients with Type 1 diabetes
    Prager, R
    Dreyer, M
    Robinson, A
    Busch, K
    Penfornis, A
    Souhami, E
    [J]. DIABETOLOGIA, 2004, 47 : A301 - A301
  • [4] Pharmacodynamics (PD) and pharmacokinetics (PK) of insulin glulisine (GLU) versus insulin lispro (IL) and regular human insulin (RHI) in patients with type 1 diabetes
    Burger, F
    Scholtz, H
    Frick, A
    Becker, RHA
    [J]. DIABETES, 2004, 53 : A557 - A557
  • [5] Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents
    Holcombe, JH
    Zalani, S
    Arora, VK
    Mast, CJ
    [J]. CLINICAL THERAPEUTICS, 2002, 24 (04) : 629 - 638
  • [6] Pharmacodynamics (PD) and pharmacokinetics (PK) of insulin glulisine compared with insulin lispro (IL) and regular human insulin (RHI) in patients with type 2 diabetes
    Becker, RHA
    Frick, AD
    Kapitza, C
    Heise, T
    Rave, K
    [J]. DIABETES, 2004, 53 : A119 - A119
  • [7] Comparison of clinical effectiveness and safety of glulisine versus insulin lispro, aspart and regular human insulin in patients with type 1 and 2 diabetes
    Walczak, J.
    Borowiack, E.
    Kolodziej, K.
    Lis, J.
    Gierczynski, J.
    Nogas, G.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A219 - A219
  • [8] Insulin Analogues Insulin Glargine and Insulin Glulisine in Type 1 Diabetes
    Schreiber, S. A.
    Fiesselmann, A.
    Bornstein, S. R.
    Landgraf, W.
    [J]. DIABETES STOFFWECHSEL UND HERZ, 2011, 20 (02): : 69 - 77
  • [9] Efficacy and safety of insulin glulisine(GLU) and insulin lispro (IL), combined with insulin glargine (GLAR) in patients with type 1 diabetes
    Dreyer, M
    Prager, R
    Robinson, A
    Busch, K
    Souhami, E
    [J]. DIABETES, 2004, 53 : A123 - A123
  • [10] Intravenous administration of insulin lispro versus regular insulin in patients with type 1 diabetes
    Stiller, R
    Kothny, T
    Gudat, UHK
    Anderson, JH
    Seger, M
    Johnson, RD
    Richardson, MS
    Haslbeck, M
    [J]. DIABETES, 1999, 48 : A115 - A115
12345